Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.
about
How I treat acquired aplastic anemiaCurrent concepts in the pathophysiology and treatment of aplastic anemiaClonal hematopoiesis in acquired aplastic anemiaEltrombopag in aplastic anemiaSystemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report.Immunosuppressive therapy for transplant-ineligible aplastic anemia patients.Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumabHigh-dose cyclophosphamide for severe aplastic anemia: long-term follow-upHorse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia.Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia.Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Efforts to prevent and halt autoimmune beta cell destruction.Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemiaRelapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donorsEltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.Recent advances in treatment of aplastic anemia.Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.Aplastica anemia and viral hepatitisEltrombopag Added to Standard Immunosuppression for Aplastic Anemia.Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience.Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantationPredicting response to immunosuppressive therapy in childhood aplastic anemia.High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseasesSevere fatigue: could it be aplastic anemia?Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia.Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptorSNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China.Clinical management of aplastic anemia.Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.
P2860
Q24617687-B236565D-6FBE-49C4-BD07-C83F468D09AEQ24685812-97668810-841D-4EE0-BC78-78F953B34081Q28079733-11D8BC89-5112-4016-829D-F9C276D7C89EQ28085299-DBBB9A12-155B-44D8-9CEF-9B48F1A0F19FQ33367435-3F3FC24A-2CFC-4774-B021-18AC91B5EF80Q33419679-EC17CCF1-4A2B-4BB6-B0CF-4BC7AC54C2E4Q33489272-7184BADA-E1C6-469F-A37F-4F15276B28EDQ33707389-625FD106-B5CC-478C-8C83-6F012EB954CCQ33747331-31778EA2-90DB-43DA-BB63-4036E1A6D0FDQ33757965-FA18FE3D-28A5-481B-8227-E3742219FD17Q33820120-0773050D-2435-44F2-875B-904DAA62352EQ33952747-3F953932-C63B-4AE0-AD95-2DAD84D86E58Q34065882-0A84B892-8A00-43A7-90BA-52FEF02B7498Q34077363-9FC15F0B-E87F-4879-BF38-FAA662FCA673Q34108254-B196A07D-09F6-4DDD-BDA0-CFFDEA3A0BEBQ34108996-DF9D3E64-5505-4423-9785-E484D65F2D17Q34164154-6382C39C-B5A5-479E-BAE9-6CB121814EF0Q34172212-B5623644-B781-470B-9D9D-2580345E1E38Q34212939-8164E1E5-B80B-4207-99EF-2377E0EB66BAQ34371142-96521598-6CC3-4F97-824D-320E47BDE24EQ34392449-3ADC1E1B-950A-4F3F-95F9-19E8A5ED62B1Q34431435-65362D25-6C49-463C-9EC5-291ED0B71ACAQ34451351-6F4DB026-DB76-4CDC-AD8A-F0829D75E203Q34488656-D40F23AD-DDCD-440D-BD58-694A361893F0Q34549277-9F125598-C882-453C-B498-44BEEB0659E6Q34555435-2D31AA39-D466-48E0-9179-6A8A4DF62F2DQ34647767-C01D443C-CA89-4501-B308-E913ECE5BF72Q34649014-189BC521-D828-417B-9E7F-0CB3FBE75448Q34890595-144465CF-95F2-47BE-96B8-4289452F882AQ34986999-CF156087-0B44-4E07-9734-65B93D9A70E8Q34989207-D6D87833-4C8C-46C6-A246-7004811E24BFQ35004982-C7393167-A996-4D05-896E-D928544EFFACQ35019920-3D08C946-660F-4433-8728-534E68ECF63CQ35080710-2F7910A9-F049-4A84-B4C2-93A2A19415CDQ35083258-35880F5A-9134-41C0-89AD-FE9CFA3C409CQ35088529-FDB3FE82-B870-4241-AE7F-9595B7AC24E7Q35112372-ED2FCA59-7B09-4EEB-8496-5A4D4D203C1FQ35193715-020C6910-3ABC-4086-8D41-7202FBFF1916Q35197402-3CCB2C6A-DA21-4444-BE95-EB27E7CCC985Q35220764-877B4F20-F394-45B3-9778-775CEE186C2C
P2860
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@en
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@nl
type
label
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@en
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@nl
prefLabel
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@en
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@nl
P2093
P356
P1476
Antithymocyte globulin and cyc ...... esponse and long-term outcome.
@en
P2093
Dean Follmann
Neal S Young
Olga Nunez
Stephen Rosenfeld
P304
P356
10.1001/JAMA.289.9.1130
P407
P577
2003-03-01T00:00:00Z